Referências
Principais artigos
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr;78(1):162-9.Texto completo Resumo
Mertz GJ, Hjelle B, Crowley M, et al. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis. 2006 Oct;19(5):437-42. Resumo
Chang B, Crowley M, Campen M, et al. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med. 2007 Apr;28(2):193-200. Resumo
Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome (HPS) 2015 case definition. 2015 [internet publication].Texto completo
Centers for Disease Control and Prevention. General hantavirus technical/clinical information: clinical manifestation. August 2012 [internet publication]Texto completo
Artigos de referência
1. Vapalahti O, Mustonen J, Lundkvist A, et al. Hantavirus infections in Europe. Lancet Infect Dis. 2003 Oct;3(10):653-61. Resumo
2. Miller MJ. Viral taxonomy. Clin Infect Dis. 1999 Oct;29(4):731-3.Texto completo Resumo
3. McCaughey C, Hart CA. Hantaviruses. J Med Microbiol. 2000 Jul;49(7):587-99.Texto completo Resumo
4. Figueiredo LT, Souza WM, Ferrés M, et al. Hantaviruses and cardiopulmonary syndrome in South America. Virus Res. 2014 Jul 17;187:43-54. Resumo
5. Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis. 2002 May 1;34(9):1224-31.Texto completo Resumo
6. Hjelle B, Goade D, Torrez-Martinez N, et al. Hantavirus pulmonary syndrome, renal insufficiency and myositis associated with infection by Bayou hantavirus. Clin Infect Dis. 1996 Sep;23(3):495-500. Resumo
7. Khan AS, Gaviria M, Rollin PE, et al. Hantavirus pulmonary syndrome in Florida: association with the newly identified Black Creek Canal virus. Am J Med. 1996 Jan;100(1):46-8. Resumo
8. Centers for Disease Control and Prevention. Reported cases of hantavirus disease: hantavirus infection in the United States. 2022 May [internet publication].Texto completo
9. Centers for Disease Control and Prevention. Multi-state outbreak of Seoul virus. Apr 2017 [internet publication].Texto completo
10. European Centre for Disease Prevention and Control. Hantavirus infection - annual epidemiological report for 2019. 2021 April European Centre for Disease Prevention and Control. Chikungunya virus disease - annual epidemiological report for 2017. April 2019 [internet publication].Texto completo
11. Abbott KD, Ksiazek TG, Mills JN. Long-term hantavirus persistence in rodent populations in central Arizona. Emerg Infect Dis. 1999 Jan-Feb;5(1):102-12.Texto completo Resumo
12. Butler JC, Peters CJ. Hantaviruses and hantavirus pulmonary syndrome. Clin Infect Dis. 1994 Sep;19(3):387-94;quiz 395. Resumo
13. Núñez JJ, Fritz CL, Knust B, et al. Hantavirus infections among overnight visitors to Yosemite National Park, California, USA, 2012. Emerg Infect Dis. 2014 Mar;20(3):386-93.Texto completo Resumo
14. World Health Organization. Hantavirus pulmonary syndrome - Argentine Republic. Jan 2019 [internet publication].Texto completo
15. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Notes from the field: contact tracing investigation after first case of andes virus in the United States — Delaware, February 2018. Oct 2018 [internet publication].Texto completo
16. Calisher CH, Mills JN, Root JJ, et al. Hantaviruses: etiologic agents of rare but potentially life-threatening zoonotic diseases. J Am Vet Med Assoc. 2003 Jan 15;222(2):163-6. Resumo
17. Howard MJ, Doyle TJ, Koster FT, et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis. 1999 Dec;29(6):1538-44.Texto completo Resumo
18. Public Health England. Andes hantavirus: epidemiology, outbreaks and guidance. 2021 May [internet publication].Texto completo
19. Martinez VP, Bellomo C, San Juan J, et al. Person-to-person transmission of Andes virus. Emerg Infect Dis. 2005 Dec;11(12):1848-53.Texto completo Resumo
20. Martinez-Valdebenito C, Calvo M, Vial C, et al. Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011. Emerg Infect Dis. 2014 Oct;20(10):1629-36.Texto completo Resumo
21. Toledo J, Haby MM, Reveiz L, et al. Evidence for human-to-human transmission of hantavirus: a systematic review. J Infect Dis. 2022 Oct 17;226(8):1362-71.Texto completo Resumo
22. Ferres M, Vial P, Marco C, et al. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile. J Infect Dis. 2007 Jun 1;195(11):1563-71.Texto completo Resumo
23. Godoy P, Marsac D, Stefas E, et al. Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome. J Virol. 2009 May;83(10):5046-55.Texto completo Resumo
24. Castillo C, Villagra E, Sanhueza L, et al. Prevalence of antibodies to hantavirus among family and health care worker contacts of persons with hantavirus cardiopulmonary syndrome: lack of evidence for nosocomial transmission of Andes virus to health care workers in Chile. Am J Trop Med Hyg. 2004 Mar;70(3):302-4.Texto completo Resumo
25. Ferrer JF, Jonsson CB, Esteban E, et al. High prevalence of hantavirus infection in Indian communities of the Paraguayan and Argentinean Gran Chaco. Am J Trop Med Hyg. 1998 Sep;59(3):438-44.Texto completo Resumo
26. Campos GM, Moro de Sousa RL, Badra SJ, et al. Serological survey of hantavirus in Jardinopolis County, Brazil. J Med Virol. 2003 Nov;71(3):417-22. Resumo
27. Muñoz-Zanzi C, Saavedra F, Otth C, et al. Serological evidence of hantavirus infection in apparently healthy people from rural and slum communities in southern Chile. Viruses. 2015 Apr 17;7(4):2006-13.Texto completo Resumo
28. Fritz CL, Young JC. Estimated incubation period for hantavirus pulmonary syndrome. Am J Trop Med Hyg. 2001 Nov;65(5):403. Resumo
29. St Jeor SC. Three-week incubation period for hantavirus infection. Pediatr Infect Dis J. 2004 Oct;23(10):974-5. Resumo
30. Borges AA, Campos GM, Moreli ML, et al. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. Microbes Infect. 2006 Jul;8(8):2324-30. Resumo
31. Bharadwaj M, Nofchissey R, Goade D, et al. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000 Jul;182(1):43-8.Texto completo Resumo
32. Green W, Feddersen R, Yousef O, et al. Tissue distribution of hantavirus antigen in naturally infected humans and deer mice. J Infect Dis. 1998 Jun;177(6):1696-700. Resumo
33. Zavasky DM, Hjelle B, Peterson MC, et al. Acute infection with Sin Nombre hantavirus without pulmonary edema. Clin Infect Dis. 1999 Sep;29(3):664-6. Resumo
34. Maes P, Clement J, Gavrilovskaya I, et al. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004;17(4):481-97. Resumo
35. Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis. 1999 Feb;179(2):295-302.Texto completo Resumo
36. Gavrilovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. J Virol. 2010 May;84(9):4832-9.Texto completo Resumo
37. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res. 2012 Jan;93(1):2-15. Resumo
38. Geimonen E, LaMonica R, Springer K, et al. Hantavirus pulmonary syndrome-associated hantaviruses contain conserved and functional ITAM signaling elements. J Virol. 2003 Jan;77(2):1638-43.Texto completo Resumo
39. Borges AA, Figueiredo LT. Mechanisms of shock in hantavirus pulmonary syndrome. Curr Opin Infect Dis. 2008 Jun;21(3):293-7. Resumo
40. Saggioro FP, Rossi MA, Duarte MIS, et al. Hantavirus infection induces a typical myocarditis that may be responsible for myocardial depression and shock in hantavirus pulmonary syndrome. J Infect Dis. 2007 May 15;195(10):1541-9.Texto completo Resumo
41. Raftery MJ, Lalwani P, Krautkrӓmer E, et al. β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps. J Exp Med. 2014 Jun 30;211(7):1485-97.Texto completo Resumo
42. Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis. 2000 May;181(5):1569-73.Texto completo Resumo
43. Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr;78(1):162-9.Texto completo Resumo
44. Mertz GJ, Hjelle B, Crowley M, et al. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis. 2006 Oct;19(5):437-42. Resumo
45. Chapman LE, Ellis BA, Koster FT, et al. Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis. 2002 Feb 1;34(3):293-304.Texto completo Resumo
46. Chang B, Crowley M, Campen M, et al. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med. 2007 Apr;28(2):193-200. Resumo
47. Centers for Disease Control and Prevention. Hantavirus: diagnostics. March 2020 [internet publication].Texto completo
48. Figueiredo LT, Moreli ML, Borges AA, et al. Evaluation of an enzyme-linked immunosorbent assay based on Araraquara virus recombinant nucleocapsid protein. Am J Trop Med Hyg. 2009 Aug;81(2):273-6.Texto completo Resumo
49. Koster F, Foucar K, Hjelle B, et al. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am J Clin Pathol. 2001 Nov;116(5):665-72.Texto completo Resumo
50. Hjelle B, Spiropoulou CF, Torrez-Martinez N, et al. Detection of Muerto Canyon virus RNA in peripheral blood mononuclear cells from patients with hantavirus pulmonary syndrome. J Infect Dis. 1994 Oct;170(4):1013-7. Resumo
51. Xiao R, Yang S, Koster F, et al. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis. 2006 Nov 15;194(10):1403-9.Texto completo Resumo
52. Ye C, Prescott J, Nofchissey R, et al. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis. 2004 Mar;10(3):478-82.Texto completo Resumo
53. Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996 Feb;24(2):252-8. Resumo
54. Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol. 1995 Jan;26(1):110-20. Resumo
55. Machado AM, Figueiredo GG, Dos Santos Junior GS, et al. Laboratory diagnosis of human hantavirus infection: novel insights and future potential. Future Virol. 2009;4:383-9.
56. Boroja M, Barrie JR, Raymond GS. Radiographic findings in 20 patients with Hantavirus pulmonary syndrome correlated with clinical outcome. AJR Am J Roentgenol. 2002 Jan;178(1):159-63.Texto completo Resumo
57. Ketai LH, Kelsey CA, Jordon K, et al. Distinguishing hantavirus pulmonary syndrome from acute respiratory distress syndrome by chest radiography: are there different radiographic manifestations of increased alveolar permeability? J Thorac Imaging. 1998 Jul;13(3):172-7. Resumo
58. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome (HPS) 2015 case definition. 2015 [internet publication].Texto completo
59. Smith HM, Reporter R, Rood MP, et al. Prevalence study of antibody to ratborne pathogens and other agents among patients using a free clinic in downtown Los Angeles. J Infect Dis. 2002;186:1673-1676. Resumo
60. Yanagihara R. Hantavirus infection in the United States: epizootiology and epidemiology. Rev Infect Dis. 1990;12:449-457. Resumo
61. Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med. 1998 Feb;26(2):409-14. [Erratum in: Crit Care Med. 1998 Apr;26(4):806.] Resumo
62. Wernly JA, Dietl CA, Tabe CE, et al. Extracorporeal membrane oxygenation support improves survival of patients with Hantavirus cardiopulmonary syndrome refractory to medical treatment. Eur J Cardiothorac Surg. 2011 Dec;40(6):1334-40.Texto completo Resumo
63. Moore SA, Dietl CA, Coleman DM. Extracorporeal life support during pregnancy. J Thorac Cardiovasc Surg. 2016 Apr;151(4):1154-60. Resumo
64. Mertz GJ, Miedzinski L, Goade D, et al. Placebo controlled, double blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004 Nov 1;39(9):1307-13.Texto completo Resumo
65. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open label experience. Ribavirin Study Group. Antivir Ther. 1999;4(4):211-9. Resumo
66. Vial PA, Valdivieso F, Ferres M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013 Oct;57(7):943-51.Texto completo Resumo
67. Vial PA, Valdivieso F, Calvo M et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther. 2015;20(4):377-86. Resumo
68. Safronetz D, Falzarano D, Scott DP, et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013 Oct;57(10):4673-80.Texto completo Resumo
69. Gracia F, Armien B, Simpson SQ, et al. Convalescent pulmonary dysfunction following hantavirus pulmonary syndrome in Panama and the United States. Lung. 2010 Oct;188(5):387-91.Texto completo Resumo
70. Pergam SA, Schmidt DW, Nofchissey RA, et al. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg. 2009;80:279-285. Resumo
71. Centers for Disease Control and Prevention. General hantavirus technical/clinical information: clinical manifestation. August 2012 [internet publication]Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal